ANI Pharmaceuticals (ANIP) Competitors

ANI Pharmaceuticals (NASDAQ:ANIP) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Does the media refer more to ANIP or ADMA?

In the previous week, ANI Pharmaceuticals had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 4 mentions for ANI Pharmaceuticals and 1 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.38 beat ANI Pharmaceuticals' score of 0.43 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, ANIP or ADMA?

ADMA Biologics has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$614.38M	3.24	-$18.52M	-$0.77	-119.06
ADMA Biologics	$426.45M	7.83	$197.67M	$0.86	16.27

Do analysts rate ANIP or ADMA?

ANI Pharmaceuticals currently has a consensus target price of $97.29, suggesting a potential upside of 6.11%. ADMA Biologics has a consensus target price of $27.67, suggesting a potential upside of 97.76%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Do insiders and institutionals have more ownership in ANIP or ADMA?

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is ANIP or ADMA more profitable?

ADMA Biologics has a net margin of 44.06% compared to ANI Pharmaceuticals' net margin of -1.37%. ADMA Biologics' return on equity of 41.01% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	-1.37%	25.03%	8.00%
ADMA Biologics	44.06%	41.01%	28.47%

Which has more volatility and risk, ANIP or ADMA?

ANI Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.

Summary

ADMA Biologics beats ANI Pharmaceuticals on 10 of the 17 factors compared between the two stocks.